The group's principal activity is to develop and commercialize autologous cellular system (acs) for the dermatological and plastic surgery markets. Acs is a process whereby a patient's own (autologous) cells are extracted, reproduced through proprietary process and then reintroduced back into the patient for specific cosmetic and medical applications. The isolagen process is designed to replenish deficiencies caused through the loss of fibroblast cells as the body ages. It reduces dermal depressions and wrinkles by replenishing the area of deficiency with millions of the patient's own new living fibroblast cells. Within weeks after the injection, the millions of new fibroblast cells will produce new collagen and elastin and will help diminish wrinkles. The group is in the development stage.
